FAQ: Clene Inc.'s Progress Toward NDA Submission for ALS Therapy CNM-Au8®
Summary
Clene Inc. is advancing toward submitting a New Drug Application (NDA) for its lead asset CNM-Au8® in treating ALS, with submission expected in Q4 2025 under the accelerated approval pathway. This represents significant progress in developing a potential therapeutic for this devastating neurodegenerative disease.
What is Clene Inc. and what does it focus on?
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis.
What is CNM-Au8® and how does it work?
CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress.
When does Clene expect to submit its NDA for CNM-Au8® in ALS?
Clene expects to submit its New Drug Application (NDA) for CNM-Au8® in ALS in the fourth quarter of 2025 under the accelerated approval pathway.
What recent progress has Clene made toward NDA submission?
Clene has emphasized progress toward NDA submission, including upcoming FDA meetings focused on extensive survival data that CNM-Au8® has generated in ALS patients and biomarker analyses as final steps toward potential submission.
Who is leading Clene Inc. and what is their commitment?
CEO Rob Etherington is leading Clene Inc., and the company maintains an unwavering commitment to the ALS community in developing an impactful therapeutic agent for this devastating disease.
Where is Clene Inc. based and where are its operations located?
Clene Inc. is based in Salt Lake City, Utah, with research & development and manufacturing operations located in Maryland.
Where can I find more information about Clene Inc. and its developments?
More information is available at www.Clene.com, and the latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN.
What is the significance of Clene’s progress with CNM-Au8® for ALS patients?
This progress represents potential hope for ALS patients as CNM-Au8® could become an approved therapeutic agent targeting the underlying mitochondrial dysfunction in this devastating neurodegenerative disease.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 203005